Clinical Trial

Carbon Ion Therapy for Peripheral Non-small Cell Lung Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 13, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
To investigate the efficacy of carbon ion therapy for stage Ia-IIa primary peripheral non-small cell lung cancer (NSCLC). The primary endpoint was progression-free survival (PFS), and the secondary endpoint was local control rate, overall survival (OS) and toxicities.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-11-10; most recent amendment 2025-06-10.
Trial Details
NCT Number NCT05613452
Lead Sponsor Shanghai Proton and Heavy Ion Center
Conditions Non-small Cell Lung Cancer
Enrollment 43 participants
Start Date 2024-09-29
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-06-13